knowledge -WSS

knowledge

author：leisure time 2025-10-02 20:59:17 - browse：25934

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Affordable Connectivity Program vital to health care, experts say

focus

explore

WSS

Stanford president's case begs question: Who takes blame?

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Group opposing PBM reform sets lobbying record

Awakening the world to the whoosh: A patient's crusade

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

A public scorecard can help hold safety

entertainment

knowledge

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Custom gene therapy hints at new path for rare disease treatments

Trump demands the U.S. pay no more for drugs than other countries … again

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Medical records are filled with copy

Indian pharmaceutical industry in denial over drug

Medical leaders decry Supreme Court decision on affirmative action

Texas Department of Public Safety speaks out on migrant abuse allegations

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA approves RSV monoclonal antibody for infants, toddlers

focus

AI can’t replace a physician’s gut feeling

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

At Orexo, a ‘turning point’ for everything but digital health

Key House panel plots a new health care package

Affordable Connectivity Program vital to health care, experts say

How Medicaid coverage policies for immigrants impact new moms

focus

Wikipedia

explore

leisure time